A study on circadian and circannual rhythmicity in the episodes of fatal pulmonary thromboembolism has been conducted in 152 cases. The data demonstrate that the incidence in the episodes of pulmonary thromboembolism, evaluated as hour and day of onset in the clinical symptoms, presents a temporal, both circadian, and circannual distribution. The greater incidence occurs in the morning hours and in the winter season. The rhythmometric analysis by "cosinor" method showed a significant circadian and circannual rhythms in incidence of episodes of fatal pulmonary thromboembolism. The temporal distribution does not seem to be casual, but the effect of interrelationship between exogenous rhythms, such as those in the haemostatic system, endogenous rhythms, such as the cold temperature, and disease. These results demonstrate that the pulmonary thromboembolism is a disease with an high "chrono-risk", i.e. it is an expectable disease in its temporal recurrence.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Low-dose Systemic Tissue-type-plasminogen-activator Compared to Conventional Anti-coagulation for the Treatment of Intermediate-high Risk Pulmonary Embolism.
Cardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFPulmonary Embolism in a Palliative Aortopulmonary Shunt.
JACC Case Rep
January 2025
Department of Adult Congenital Heart Disease, University of Virginia, Charlottesville, Virginia, USA.
A 44-year-old man with a history of tricuspid atresia and discontinuous pulmonary arteries with palliative correction from a Waterston procedure and a modified central shunt presented with back pain, fevers, dyspnea, and cough. Treatment for pneumonia was unsuccessful. On computed tomography angiography he was found to have a subacute pulmonary embolism, potentially iatrogenic.
View Article and Find Full Text PDFThe routine use of Rivaroxaban as thromboprophylaxis following endovenous thermal ablation.
Vasa
January 2025
Department of Vascular Surgery, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
We investigated the safety and efficacy of rivaroxaban as routine thromboprophylaxis after endovenous thermal ablation (EVTA). Adhering to the PRISMA 2020 guidelines, we conducted a systematic review for studies published up to April 2024. Primary endpoints included endovenous heat-induced thrombosis (EHIT) class ≥ II, deep vein thrombosis (DVT), major and minor bleeding and the composite endpoint of major thromboembolic complications including any incidents of EHIT ≥ III, DVT or pulmonary embolism (PE).
View Article and Find Full Text PDFLeukoglycemic Index and Its Prognostic Implications in Diabetic and Nondiabetic Patients with Acute Pulmonary Embolism.
Med Sci Monit
January 2025
Department of Emergency Medicine, Sakarya University Faculty of Medicine, Adapazari, Turkey.
BACKGROUND The leuko-glycemic index (LGI) combines the white blood cell count and blood glucose levels and is calculated by multiplying the 2 values and dividing them by 1000. This study aimed to compare the prognostic value of the LGI in 199 patients with acute pulmonary embolism (APE) with and without diabetes mellitus. MATERIAL AND METHODS This study was conducted retrospectively on 199 patients who were admitted to the Emergency Department of Sakarya Training and Research Hospital between January 1, 2019, and December 31, 2022, and received a diagnosis of APE by pulmonary angiography.
View Article and Find Full Text PDFCorrigendum to "Phillyrin and its metabolites treat pulmonary embolism by targeting PLCβ3 to inhibit platelet activation" [J. Ethnopharmacol. 333 (2024) 118457].
J Ethnopharmacol
January 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!